{
  "study_id": "STU-D-302",
  "study_name": "STUDY-302",
  "sponsor": "SPONSOR Pharmaceuticals Inc.",
  "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of STU101 Administered as Adjunctive Therapy in Focal Onset Seizures in Pediatric and Adolescent Subjects Aged 2 to <18 Years",
  "phase": "3",
  "indication": "Focal Onset Seizures (Epilepsy)",
  "therapeutic_area": "Neurology",
  "indication_level_quotes": "1320",
  "therapeutic_area_quotes": "12295",
  "population": {
    "age_range": "2 to <18 years",
    "condition": "Focal onset seizures",
    "inclusion_highlights": [
      "Diagnosis of focal epilepsy",
      "History of uncontrolled focal onset seizures despite at least one prior ASM",
      "Stable dose of current ASMs",
      "Body weight \u2265 10 kg"
    ]
  },
  "design": {
    "randomization": "Yes",
    "control": "Placebo-controlled",
    "blinding": "Double-blind",
    "arms": 2,
    "multicenter": true
  },
  "total_visits": 52,
  "total_weeks": 52,
  "visit_schedule_json": "patient_burden_mapper_visit_schedule_FULL.json"
}